The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs-Reference-Cited by-同舟云学术

The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs

Published:2021-06 Issue: Volume:188 Page:114516
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Wu Chung-Pu,Hung Tai-Ho,Lusvarghi Sabrina,Chu Yi-Hsuan,Hsiao Sung-Han,Huang Yang-Hui,Chang Yu-Tzu,Ambudkar Suresh V.

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference82 articles.

1. Targeting multidrug resistance in cancer;Szakacs;Nat. Rev.,2006

2. The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy;Wu;Mol. Pharm.,2011

3. Revisiting the role of ABC transporters in multidrug-resistant cancer;Robey;Nat. Rev. Cancer,2018

4. ABC transporters and human disease;Gottesman;J. Bioenerg. Biomembr.,2001

5. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux;Agarwal;J. Pharmacol. Exp. Ther.,2010

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced Strategies for Strengthening the Immune Activation Effect of Traditional Antitumor Therapies;ACS Biomaterials Science & Engineering;2024-07-03

2. The influence of drug-induced metabolic enzyme activity inhibition and CYP3A4 gene polymorphism on aumolertinib metabolism;Frontiers in Pharmacology;2024-05-24

3. Exploring the potential of P-glycoprotein inhibitors in the targeted delivery of anti-cancer drugs: A comprehensive review;European Journal of Pharmaceutics and Biopharmaceutics;2024-05

4. Epidermal Growth Factor Receptor Inhibitor Mobocertinib Resensitizes Multidrug-Resistant Cancer Cells by Attenuating the Human ATP-Binding Cassette Subfamily B Member 1 and Subfamily G Member 2;ACS Pharmacology & Translational Science;2023-12-05

5. Aumolertinib: effective treatment for asymptomatic pulmonary giant cell carcinoma with EGFR L858R mutation - a case report;Frontiers in Oncology;2023-11-27